Vical Inc., of San Diego, said the FDA deemed its investigational antifungal, VL-2397, would be eligible for a limited use indication (LUI) approval, assuming a successful outcome of a single phase II trial carried out in accordance with a protocol and statistical analysis plan consistent with the agency’s advice.